Published • loading... • Updated
Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI
Pfizer will gain early access to Chai-3 and a custom model that uses Pfizer’s proprietary data to speed biologics discovery, the company said.
Summary by Enid News & Eagle
3 Articles
3 Articles
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes has learned.
·United States
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left1Leaning Right0Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 33%
C 67%
Factuality
To view factuality data please Upgrade to Premium
